Regentis Biomaterials (RGNT) withdraws Form F-1 and halts planned offering

Rhea-AI Filing Summary

Regentis Biomaterials Ltd., a foreign private issuer based in Israel, reports that it has requested withdrawal of its Registration Statement No. 333-295510 on Form F-1, effective June 15, 2026. The company has decided not to pursue the public offering that was planned under this registration.

Insights

Cross-border capital markets analyst

Regentis is stepping back from a planned U.S. public offering by withdrawing its Form F-1.

Regentis Biomaterials Ltd. has asked the U.S. Securities and Exchange Commission to withdraw its Form F-1 Registration Statement No. 333-295510, effective June 15, 2026. This means the company is halting the specific public offering that filing supported.

The filing does not explain why the offering will not proceed or whether Regentis might consider alternative financing or future offerings. It simply formalizes that the prior plan to go public via this Form F-1 is no longer active.

Investors and stakeholders now know that any expectations tied to that particular public offering are no longer applicable, and any future capital-raising plans would require new disclosures in subsequent regulatory filings.

Key Figures

Registration Statement number: 333-295510 Effective withdrawal date: June 15, 2026

2 metrics

Registration Statement number 333-295510 Form F-1 withdrawn by Regentis Biomaterials

Effective withdrawal date June 15, 2026 Date withdrawal of Form F-1 became effective

Key Terms

Form 6-K, foreign private issuer, Registration Statement, Form F-1, +1 more

5 terms

Form 6-K regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Registration Statement regulatory

"a request for withdrawal of the Registration Statement No. (File No. 333-295510) on Form F-1"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Form F-1 regulatory

"withdrawal of the Registration Statement No. (File No. 333-295510) on Form F-1"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

public offering financial

"The Company has determined not to pursue the public offering to which the Registration Statement relates."

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/15/2026 - 11:57 AM Accepted by SEC EDGAR 06/15/2026 - 11:57 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2026

Commission file number: 001-42834

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On June 15, 2026, Regentis Biomaterials Ltd. (the “Company”) filed with the Securities and Exchange Commission (the “Commission”) a request for withdrawal of the Registration Statement No. (File No. 333-295510) on Form F-1 (as amended and together with the exhibits and amendments thereto, the “Registration Statement”) effective as of June 15, 2026. The Company has determined not to pursue the public offering to which the Registration Statement relates.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.
Date: June 15, 2026	By:	/s/ Ori Gon
	Name:	Ori Gon
	Title:	Chief Financial Officer

2